Consistent with our scRNA-seq data, CD11b+ CD33+ cells had higher expression levels of PD1, PD-L1, PVR, and CD226 in TILs, as compared with CD11b+ CD33+ cells from PBMCs of GBM patients and HDs, most notably for PD-L1 and CD226 expression (Figure 6D). This evidence concerns the gene CD33 and glioblastoma.